References
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765–781 (2010).
- Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R; the EUROCARE Working Group. Cancer prevalence estimates in Europe at the beginning of 2000. Ann. Oncol. 24(6), 1660–1666 (2013).
- D’Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N. Engl. J. Med. 367(7), e11 (2012).
- Perdonà S, Bruzzese D, Ferro M et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73(3), 227–235 (2013).
- Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr. Drug Targets 13(13), 1676–1686 (2012).
- Bedoya DJ, Mitsiades N. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. Onco. Targets. Ther. 6, 9–18 (2013).
- Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur. Urol. 53(6), 1129–1137 (2008).
- Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J. Clin. Oncol. 30(6), 644–646 (2012).
- Stapleton AM, Timme TL, Gousse AE et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res. 3(8), 1389–1397 (1997).
- MacGrogan D, Bookstein R. Tumour suppressor genes in prostate cancer. Semin. Cancer Biol. 8(1), 11–19 (1997).
- Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30(6), 637–643 (2012).
- Di Lorenzo G, Buonerba C. Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. Eur. Urol. 63(5), 961 (2013).
- Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev. Anticancer Ther. 11(1), 25–28 (2011).
- Extra JM, Antoine EC, Vincent-Salomon A et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8), 799–809 (2010).
- Bennouna J, Sastre J, Arnold D et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 14(1), 29–37 (2013).